Pichia-derived human CYPs
Streamline your toxicity screening, metabolite synthesis or late-stage functionalization with our Human CYP Panel
Human CYP Panel
Boost your MedChem work with our Human CYP Panel. Aminoverse offers a curated selection of 8 major human cytochrome P450 enzymes CYP1A1, CYP1A2, CYP2C8, CYP2C9, CYP2C19, CYP2E1, CYP2D6, and CYP3A enabling efficient assessment of metabolic degradation products in toxicity screens, synthesis of specific compounds or drug discovery programs.
- Human CYPs for industrial application
- Available from mg to kg scale
- CASE STUDIES
Proven Product Performance & Innovation
DRUG DISCOVERY
How can I get to my metabolite faster using enzymes?
In drug discovery, the final sprint from lead optimization to candidate selection often depends on rapidly accessing metabolites, analogs, and late-stage functionalized derivatives. You often face the same, very familiar challenge...
QUALITY CONTROL SOP
I need a robust and reliable gold standard assay to quality control my product
In high-stakes analytical workflows, data integrity is strictly dictated by the robustness of your assay SOP. Variability in analyte detection, particularly when relying on standard commercial kits, often compromises precision, leading to inconsistent results and downstream regulatory friction. To ensure technical rigor,...
INCREASE THROUGHPUT
How can I effectively reduce the costs of analyzing samples after downstream processing (DSP)?
For recombinantly produced biologics, the primary hurdle is mitigating residual HCP activity of lipases and esterases that threatens formulation stability. Current workflows often rely on capital-intensive proteomics or weeks-long incubation studies...
WHY CYP ENZYMES?
Cytochrome P450 monooxygenases (CYPs) are a heme-containing superfamily of enzymes that catalyze the activation of molecular oxygen to perform mixed-function oxidations. Relying on NAD(P)H for electron regeneration, these biocatalysts facilitate complex transformations - including C-hydroxylation, N-, O-, and S-dealkylation, and epoxidation - on diverse substrates such as xenobiotics, steroids, and fatty acids. Their ability to functionalize non-activated C-H bonds provides a precise alternative to traditional chemical oxidation, which often lacks the regioselectivity required for complex molecular scaffolds.
WHY OUR CYPs ARE BETTER?
Typically produced in E. coli in low quantities, our CYPs are recombinantly expressed in specialized Komagataella phaffii (Pichia pastoris) strains. Supplied as whole-cell biocatalyst, Pichia-derived CYPs achieve higher performance at lower material input.
The Human CYP Panel delivers 8 major human isoforms (1A1, 1A2, 2C8, 2C9, 2C19, 2D6, 2E1, and 3A4) in a ready-to-screen format.
Ideally suited for toxicity screens, metabolite synthesis and late-stage derivatization, the CYP platform is mechanistically complementary to our UPOs and KGOs, extending the accessible product scope.
Any CYP can be scaled to kilogram quantities to give way for both scaled reaction and high through-put processes.
- SCALE-UP READY
From mg screening to kg enzyme powder supply
Start with milligram-level enzyme tests, then move to kilogram powder quantities for pilot and production runs. Curated panels, reliable supply, and scale-ready delivery - all from one partner.
- our enzyme ProductS
Check out our other enzyme products
CYPs are essential to pharmaceutical applications
When you are tired of the poor performance of commercially available CYPs, our Pichia-derived human CYPs are worth a look. Reach out to Rainer for a call.
